Drugs Made In America Acquisition II Cash Flow Statement
NASDAQ: DMIIFinanceBlank ChecksUSD
10.190.00 (0.00%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Drugs Made In America Acquisition II free cash flow
In fiscal 2025, Drugs Made In America Acquisition II generated -$1.0 million of operating cash flow. That left free cash flow of -$1.0 million.
Summary generated from market data by MetaCap's automated system. Methodology
Drugs Made In America Acquisition II cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 |
|---|---|
| Net Income | 4.19M |
| Net Income growth (YoY) | — |
| Change in Working Capital | 187.70K |
| Operating Cash Flow | -1.02M |
| Investing Cash Flow | -500.00M |
| Financing Cash Flow | 501.00M |
| Net Change in Cash | -16.81K |
| Free Cash Flow | -1.02M |
Values in USD; B = billions, M = millions. Fiscal periods follow DMII's reporting calendar. What is a cash flow statement?